Screening and Management of PTLD
Authors:
- 21 October 2023
- journal article
- review article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (11) , 2316-2328
Abstract
Posttransplant lymphoproliferative disorder (PTLD) represents a heterogeneous group of lymphoproliferative diseases occurring in the setting of immunosuppression following hematopoietic stem cells transplant and solid organ transplantation. Despite its overall low incidence, PTLD is a serious complication following transplantation, with a mortality rate as high as 50% in transplant recipients. Therefore, it is important to establish for each transplant recipient a personalized risk evaluation for the development of PTLD based on the determination of Epstein-Barr virus serostatus and viral load following the initiation of immunosuppression. Due to the dynamic progression of PTLD, reflected in the diverse pathological features, different therapeutic approaches have been used to treat this disorder. Moreover, new therapeutic strategies based on the administration of virus-specific cytotoxic T cells have been developed. In this review, we summarize the available data on screening and treatment to suggest a strategy to identify transplant recipients at a higher risk for PTLD development and to review the current therapeutic options for PTLD.Keywords
This publication has 188 references indexed in Scilit:
- Successful treatment of central nervous system PTLD with rituximab and cranial radiotherapyPediatric Nephrology, 2013
- Epidemiology and Morbidity of Epstein-Barr Virus Infection in Pediatric Renal Transplant Recipients: A Multicenter, Prospective StudyClinical Infectious Diseases, 2012
- Epstein-Barr Virus Gene Expression, Human Leukocyte Antigen Alleles and Chronic High Viral Loads in Pediatric Renal Transplant PatientsTransplantation, 2011
- Post-transplant lymphoproliferative disease (PTLD): Pharmacological, virological and other determinantsPharmacological Research, 2011
- Risk factors for early‐onset and late‐onset post‐transplant lymphoproliferative disorder in kidney recipients in the United StatesAmerican Journal of Hematology, 2010
- Detection of Epstein–Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantationJournal of Clinical Virology, 2009
- Gene Expression Profiling of Epstein-Barr Virus-positive and -negative Monomorphic B-cell Posttransplant Lymphoproliferative DisordersDiagnostic Molecular Pathology, 2007
- The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancersJournal of Cancer Research and Clinical Oncology, 2007
- Monitoring of Epstein–Barr Viral Load in Pediatric Heart and Lung Transplant Recipients by Real-time Polymerase Chain ReactionThe Journal of Heart and Lung Transplantation, 2005
- Epstein–Barr virus‐related post‐transplant lymphoproliferative disease in solid organ transplant recipients, 1988–97: A Canadian multi‐centre experiencePediatric Transplantation, 2001